Fibromyalgia is no longer considered a diagnosis of exclusion, though it was treated as one for decades. The 2016 revision to the American College of Rheumatology (ACR) diagnostic criteria explicitly states that “a diagnosis of fibromyalgia is valid irrespective of other diagnoses” and “does not exclude the presence of other clinically important illnesses.” In practice, though, many patients still experience a drawn-out process of ruling out other conditions before getting a fibromyalgia diagnosis, which is why the confusion persists.
What “Diagnosis of Exclusion” Actually Means
A true diagnosis of exclusion is one a doctor can only make after systematically eliminating every other possible explanation for your symptoms. Under that framework, fibromyalgia would be a label of last resort, something you’re told you have only because nothing else fits. For years, that’s exactly how it worked. Because there’s no single blood test or imaging scan that confirms fibromyalgia, doctors would order round after round of labs, and if everything came back normal, they’d land on fibromyalgia almost by default.
That approach had real consequences. Between 2008 and 2011, the average time from first symptoms to an official fibromyalgia diagnosis was 6.4 years. Patients bounced between specialists, often feeling dismissed or told their pain wasn’t real. The diagnosis-of-exclusion model contributed directly to that delay.
How Modern Criteria Changed the Picture
The shift began in 2010, when the ACR introduced criteria that could identify fibromyalgia based on what it is rather than what it isn’t. These criteria use two scoring tools. The Widespread Pain Index (WPI) asks you to identify painful areas across 19 body regions, scored from 0 to 19. The Symptom Severity Scale (SSS) rates the severity of fatigue, unrefreshing sleep, and cognitive problems on a scale of 0 to 12. A diagnosis requires either a WPI of 7 or higher with an SSS of 5 or higher, or a WPI of 4 to 6 with an SSS of 9 or higher. Symptoms must have been present at a consistent level for at least three months, and pain must be spread across at least four of five body regions.
The 2016 revision went further by removing language that had confused clinicians about whether other conditions needed to be ruled out first. The updated criteria explicitly eliminated that recommendation. This means a doctor can diagnose fibromyalgia alongside rheumatoid arthritis, lupus, or any other condition. It doesn’t have to stand alone.
Why Doctors Still Order Blood Tests
Even though fibromyalgia has its own diagnostic criteria, your doctor will likely still run some lab work. This isn’t because fibromyalgia requires a negative test result. It’s because several other conditions cause symptoms that overlap heavily with fibromyalgia, and identifying them changes your treatment.
Common tests include a complete blood count (CBC), inflammatory markers like erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) to screen for inflammatory conditions such as polymyalgia rheumatica, and thyroid hormone levels, since both underactive and overactive thyroid function can cause fatigue and muscle soreness. These tests aren’t used to diagnose fibromyalgia. They’re ordered when your symptoms, history, or physical exam suggest something else might also be going on.
The distinction matters: testing to make sure you don’t have untreated hypothyroidism is good medicine. Refusing to diagnose fibromyalgia until every conceivable alternative has been eliminated is a different thing entirely, and it’s the pattern the updated criteria were designed to break.
Fibromyalgia Has a Biological Basis
Part of the reason fibromyalgia was historically treated as a catch-all “we don’t know what’s wrong” label is that its underlying biology wasn’t well understood. That’s changed considerably. Fibromyalgia is now recognized as a disorder of pain processing, driven primarily by two mechanisms: central sensitization and impaired pain inhibition.
Central sensitization means your nervous system amplifies pain signals. In people with fibromyalgia, the neurons in the spinal cord become hyperexcitable, responding more intensely to both painful and non-painful input. Brain imaging studies illustrate this clearly. When researchers applied the same amount of pressure to the thumbnails of people with and without fibromyalgia, those with fibromyalgia rated the sensation as significantly more painful, and their brain scans showed activation in far more pain-related areas.
At a chemical level, people with fibromyalgia have two to three times the normal levels of substance P, a neurotransmitter that amplifies pain signals, in their spinal fluid. They also show lower levels of serotonin metabolites, pointing to dysfunction in the brain’s natural pain-dampening system. In healthy people, applying a painful stimulus to one part of the body actually raises pain thresholds elsewhere, a built-in “volume knob” that turns down pain signals. In fibromyalgia, that mechanism doesn’t work. Pain thresholds stay the same, meaning the body loses one of its key tools for filtering out unnecessary pain.
How It Overlaps With Other Conditions
One of the strongest arguments against treating fibromyalgia as a pure exclusion diagnosis is how frequently it coexists with other diseases. A large meta-analysis found that about 21% of people with rheumatoid arthritis, 18% of those with psoriatic arthritis, and 13% of those with axial spondyloarthritis also have fibromyalgia. If fibromyalgia could only be diagnosed after excluding these conditions, a significant portion of patients would never receive it.
This coexistence also has practical implications for treatment. Someone with both rheumatoid arthritis and fibromyalgia needs different strategies for each. Anti-inflammatory medications may control joint damage from RA but won’t address the central sensitization driving fibromyalgia pain. Recognizing both conditions allows for a more complete treatment plan.
What a Positive Diagnosis Looks Like
Rather than being defined by the absence of other findings, fibromyalgia has a recognizable clinical profile. The core features are chronic widespread pain, severe fatigue, disrupted sleep, and cognitive difficulties often called “fibro fog,” which typically involves problems with attention and executive function. Many people also experience heightened sensitivity to touch or pressure (where normally painless sensations become painful), muscle stiffness, headaches, irritable bowel symptoms, and mood disturbances like anxiety or depression.
On physical examination, the main finding is diffuse tenderness without the joint swelling, redness, or structural damage you’d see in inflammatory arthritis. Specialized testing like quantitative sensory testing can measure pain thresholds objectively, confirming the heightened sensitivity that defines the condition. These tools aren’t routinely used in primary care, but they exist and further support fibromyalgia as a condition with measurable physical findings.
Seeing a medical specialist rather than relying solely on a primary care provider improves your odds of diagnosis. Data from national outpatient surveys found that visits with medical care specialists had 50% higher odds of resulting in a fibromyalgia diagnosis compared to primary care visits. Surgical specialists, on the other hand, had 71% lower odds of diagnosing it, likely because their focus and training lie elsewhere.
The Gap Between Guidelines and Practice
The official criteria have moved away from the exclusion model, but clinical practice hasn’t fully caught up. Many doctors were trained under the older framework and still approach fibromyalgia as something to consider only after everything else has been crossed off the list. This contributes to the years-long diagnostic delays that remain common. The significant lag between symptom onset and diagnosis delays access to treatments that can meaningfully improve quality of life.
If you’ve been told that fibromyalgia is “just a diagnosis of exclusion,” it’s worth knowing that the experts who write the criteria disagree. The condition has defined symptom thresholds, identifiable neurobiological mechanisms, and a clinical profile distinct enough to diagnose alongside other diseases rather than only in their absence.